INCB177054 in solid tumors · n=9
Reason given: This was a strategic business decision. There were no safety concerns contributing to this decision.
INCB099280 in advanced solid tumors · n=5
Reason given: This was a strategic business decision. There were no safety concerns contributing to this decision.
INCAGN01876 in metastatic head and neck squamous cell carcinoma · n=0
Reason given: Business decision; no safety concerns
Ruxolitinib cream in hand eczema · n=0
Reason given: Business decision; no safety concerns.
Ruxolitinib cream in chronic hand eczema (che) · n=0
Reason given: Business decision; no safety concerns
parsaclisib in follicular lymphoma ( fl) · n=0
Reason given: This study was withdrawn due to a business decision.
Pemigatinib in glioblastoma · n=83
Reason given: Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.
PATHWAYPhase 3 · started 2022 · terminated parsaclisinib in warm autoimmune hemolytic anemia (waiha) · n=13
Reason given: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
parsaclisib in mantle cell lymphoma · n=0
Reason given: business decision; no enrolled patients
OptimusPhase 2 · started 2022 · terminated retifanlimab in urothelial carcinoma · n=30
Reason given: Business Decision. No safety concerns contributed to this decision.
topMINDPhase 1/2 · started 2021 · terminated tafasitamab in chronic lymphocytic leukemia · n=54
Reason given: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
INCB086550 in non small cell lung cancer · n=16
Reason given: Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
LIMBERPhase 1/2 · started 2021 · terminated INCB000928 in myelodysplastic syndromes · n=22
Reason given: Strategic Business Decision
Pemigatinib in advanced malignancies · n=10
Reason given: A business decision due to availability of commercial drug and other options for accessing study drug treatment.
parsaclisib in myelofibrosis · n=177
Reason given: The study was terminated due to futility.
parsaclisib in myelofibrosis · n=252
Reason given: The study was terminated due to futility.
itacitinib in myelofibrosis · n=18
Reason given: The decision to close the study was made due to the expiration of remaining drug supply.
Retifanlimab in non-small cell lung cancer · n=0
Reason given: Sponsor Strategic/Business Decision
Placebo in covid-19 · n=211
Reason given: Study terminated by sponsor
Pemigatinib in metastatic urothelial carcinoma · n=7
Reason given: The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.
Itacitinib in bronchiolitis obliterans syndrome · n=23
Reason given: Business Decision
Itacitinib in acute graft-versus-host disease · n=2
Reason given: The study was terminated due to insufficient efficacy in a separate phase III study
Pemigatinib in advanced or metastatic solid tumors · n=1
Reason given: The study was closed due to lack of enrollment.
Pemigatinib in solid tumor malignancy · n=111
Reason given: A business decision was made to to discontinue further enrollment. There were no safety concerns that contributed to this decision.
INCB001158 in relapsed or refractory multiple myeloma · n=15
Reason given: This decision follows recruitment difficulties. No safety-related concerns impacted this decision.
Pemigatinib in unresectable cholangiocarcinoma · n=167
Reason given: The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.
Parsaclisib in pemphigus vulgaris · n=0
Reason given: The study was withdrawn due to insufficient interest in study participation due to recent approval in this rare condition.
Itacitinib in chronic graft-versus-host disease · n=155
Reason given: The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision.
Itacitinib in moderate to severe ulcerative colitis · n=0
Reason given: Study withdrawn due to lack of recruitment. No patients enrolled. No safety concerns.
Epacadostat in solid tumors · n=11
Reason given: A business decision made by Incyte after analysis of data from a sister study.
INCB001158 in solid tumors · n=5
Reason given: Study was terminated early based on emerging data with epacadostat and pembrolizumab.
Nivolumab in lung cancer · n=2
Reason given: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
Nivolumab in head and neck cancer · n=0
Reason given: Study was cancelled prior to enrolling any patients.
INCAGN01876 in advanced malignancies · n=10
Reason given: The study was terminated due to emergent data from another study and unrelated to safety.
Ruxolitinib in mpn (myeloproliferative neoplasms) · n=12
Reason given: Enrollment issues
Azacitidine in solid tumors · n=70
Reason given: Study terminated by Sponsor
Parsaclisib in mpn (myeloproliferative neoplasms) · n=74
Reason given: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
INCB057643 in solid tumors · n=137
Reason given: Study terminated due to safety issues.
INCB059872 in solid tumors and hematologic malignancy · n=116
Reason given: Strategic Business Decision
INCB053914 in solid tumors · n=97
No reason recorded in the registry.
Placebo Cream in alopecia areata · n=90
Reason given: The study was terminated early based on the results of a planned interim analysis.
INCB040093 Monotherapy in refractory hodgkin lymphoma · n=8
Reason given: A decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma.
INCB054329 Monotherapy in solid tumors and hematologic malignancy · n=69
Reason given: As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.
Pemigatinib in lung cancer · n=201
No reason recorded in the registry.
Itacitinib in solid tumors and hematologic malignancy · n=0
Reason given: Study withdrawn before enrolling first patient
Itacitinib in nsclc (non-small cell lung carcinoma) · n=9
Reason given: Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.
INCB052793 in solid tumors · n=83
No reason recorded in the registry.
Ruxolitinib in pancreatic cancer · n=86
Reason given: The safety committee found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.
INCB047986 in rheumatoid arthritis · n=3
Reason given: Business decision.
Ruxolitinib in breast cancer · n=149
Reason given: The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.
Ruxolitinib in crc (colorectal cancer) · n=396
Reason given: Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.
Ruxolitinib in pancreatic cancer · n=321
Reason given: The study was terminated early based on the results of the planned interim analysis.
Ruxolitinib in nsclc (non-small cell lung carcinoma) · n=76
Reason given: The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.
INCB047986 in mds (myelodysplastic syndrome) · n=6
Reason given: Business decision.
Epacadostat in ovarian cancer · n=83
Reason given: Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.
Epacadostat in melanoma · n=50
Reason given: Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.
INCB007839 300mg BID in breast cancer · n=20
Reason given: Incyte has suspended development of the compound.
Ruxolitinib in myeloproliferative neoplasm (mpn) · n=73
Reason given: Termination of the clinical trial by sponsor.
INCB019602 in type 2 diabetes · n=48
Reason given: Study ended after diabetes development plan review. .
Ruxolitinib in prostate cancer · n=22
Reason given: According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.
INCB007839 in breast cancer · n=68
Reason given: Incyte suspended development of the compound.
DECLAREPhase 2 · started 2006 · terminated Dexelvucitabine in hiv infections · n=250
Reason given: Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC.